BNR

Burning Rock Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.00
+0.20
+0.65%
Opening 10:07 10/30 EDT
OPEN
31.05
PREV CLOSE
30.80
HIGH
31.05
LOW
30.60
VOLUME
6.44K
TURNOVER
--
52 WEEK HIGH
32.40
52 WEEK LOW
18.64
MARKET CAP
3.16B
P/E (TTM)
-64.6901
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Burning Rock to Present Validation Data of Magnis BR at the AMP Annual Meeting
GUANGZHOU, China, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that analytical validation data of its fully-automated NGS library preparation platform, Magnis BR, will be presented at the Association for Molecular Pathology
GlobeNewswire · 9h ago
Burning Rock reports preliminary Q3 revenue slightly above estimates
Burning Rock (BNR) expects Q3 revenue in between $17.4M to $18.1M vs. a consensus of $17.1M.This represents an increase of ~16.2% as compared to the same period in 2019, using
Seekingalpha · 10/21 05:32
Burning Rock to Present Data on Its Early Detection ELSA-seq at ESMO Asia Virtual Congress 2020
GUANGZHOU, China, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that new data for its early detection ELSA-seq test will be presented at the upcoming European Society for Medical Oncology (ESMO) Asia Virtual Congress, on
GlobeNewswire · 10/21 01:30
Burning Rock Announces Preliminary Third Quarter 2020 Results and Schedules Earnings Release on November 20, 2020
GUANGZHOU, China, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2020 before the U.S. market opens on November 20, 2020. Following the release, company management will host a conference call at 8:00 a.m. ET (9:00 p.m. Hong Kong time) the same day to discuss (i) its financial results for the third quarter of 2020 and (ii) its cancer early detection data to be released at the upcoming European Society for Medical Oncology (ESMO) Asia Virtual Congress 2020. Burning Rock expects to report revenues between RMB118 million (US$17.4 million) and RMB123 million (US$18.1 million) for the third quarter of 2020. This represents an increase of 16.2% as compared to the same period in 2019 and an increase of 12.6% as compared to the second quarter of 2020, calculated using the midpoint of the estimated range.Burning Rock has not completed preparation of its financial statements for the third quarter of 2020. The above revenue range is preliminary, inherently uncertain and subject to change as the Company completes its financial results for the third quarter of 2020.Details of the conference call are as follows:International:+65 67135090 U.S.:+1 8456750437 U.K.:+44 2036214779 Hong Kong:+852 30186771 China Mobile:4006208038 China Landline:8008190121 Conference ID:5637209 A replay of the third quarter 2020 conference call will be available for two weeks (dial-in number: +61 2 8199 0299; same conference ID as shown above).Please visit the company’s investor relations website at https://ir.brbiotech.com/news-events/news-releases on November 20, 2020 to view the earnings release prior to the conference call.About Burning RockBurning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.For more information about Burning Rock, please visit: www.brbiotech.com.Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. CONTACT: Contact: minying.cheng@brbiotech.com
GlobeNewswire · 10/21 01:30
Xtant Medical to Issue Third Quarter 2020 Financial Results on October 29, 2020
BELGRADE, Mont., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2020, before the open of the financial markets on Thursday, October 29, 2020. Sean Browne, President and Chief Executive Officer, and Greg Jensen, Vice President, Finance and Chief Financial Officer, will host a conference call on Thursday, October 29 at 9:00 AM ET to review results.Conference Call Details Date: Thursday, October 29, 2020 – 9:00 AM ET Dial-in: 877-407-6184 International dial-in: 201-389-0877 Conference Call Name: Xtant Medical Third Quarter 2020 Financial Results Webcast Registration: Click HereFollowing the live call, a replay will be available on the Company’s website, www.xtantmedical.com, under “Investor Info.”About Xtant Medical Holdings, Inc.Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.Investor Relations ContactDavid Carey Lazar FINN Partners Ph: 212-867-1768 Email: david.carey@finnpartners.com
GlobeNewswire · 10/20 12:30
Xtant Medical Regains Compliance with NYSE American Continued Listing Standards
BELGRADE, Mont., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it received notification from the NYSE American LLC yesterday that the Company
GlobeNewswire · 10/06 12:00
Xtant Medical Announces Closing of Debt Restructuring
BELGRADE, Mont., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has completed its previously announced debt restructuring transaction
GlobeNewswire · 10/01 21:05
The Pandemic Speeds Up the Health-Care Revolution
The drive to quickly conquer Covid-19 has accelerated innovation across the health-care sector. Barron’s roundtable experts highlight the most promising...
marketwatch.com · 09/26 00:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BNR. Analyze the recent business situations of Burning Rock Biotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BNR stock price target is 31.08 with a high estimate of 31.52 and a low estimate of 30.64.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 15.73M
% Owned: 15.42%
Shares Outstanding: 101.99M
TypeInstitutionsShares
Increased
0
0
New
45
15.73M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BNR
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Burning Rock Biotech Ltd(ADR) stock information, including NASDAQ:BNR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNR stock methods without spending real money on the virtual paper trading platform.